Hepatoma arterial-embolisation (HAP) Score
HAP Score is a simple score which stratifies, patient with with HCC, who will receive their first TACE. It has 4 prognostic factors
Liver related variables – albumin and bilirubin
Tumor related variables- AFP (alpha-fetoprotein), and tumor size
Patients are then categorizes into low-, intermediate-, high-, and very high-risk groups with average survival of 27.6, 18.5, 9.0, and 3.6 months respectively.¹
| Prognostic Factors | Points |
|---|---|
| Albumin < 36 g/dL | 1 |
| AFP > 400 ng/ml | 1 |
| Bilirubin > 17 µmol/L | 1 |
| Maximum Tumor Diameter > 7 cm | 1 |
| HAP Classification | Points |
| HAP A | 0 |
| HAP B | 1 |
| HAP C | 2 |
| HAP D | > 2 |
Patients with a HAP score of C or D were classified into poor prognosis groups. These groups were unlikely to derive significant benefits from transarterial chemoembolization (TACE) and may instead benefit more from systemic therapy or supportive care.¹
- Kadalayil L, Benini R, Pallan L, O’beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Annals of oncology. 2013 Oct 1;24(10):2565-70.
- Karademir S. Staging of hepatocellular carcinoma. Hepatoma Res. 2018;4:58.
- Kinoshita, Akiyoshi et al. “Staging systems for hepatocellular carcinoma: Current status and future perspectives.” World journal of hepatology vol. 7,3 (2015): 406-24. doi:10.4254/wjh.v7.i3.406